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Edited by Barry HalliwellAbstract Fasting is characterized by disrupted thyroid feed-
back, with suppressed levels of thyroid hormones and paraven-
tricular thyrotropin releasing hormone (TRH). We found that
third ventricle administration of the deiodinase inhibitor, iopa-
noic acid, dose-dependently reduced deiodinase type II (DII)
activity selectively in the hypothalamus. This suppression of
DII by iopanoic acid during fasting prevented elevated DII activ-
ity and blunted the decline in hypothalamic TRH mRNA levels.
Because fasting-induced elevation in hypothalamic DII activity is
paralleled by increased hypothalamic T3 concentration, our
study suggests that T3 formation by DII in the hypothalamus
is the cause of disrupted thyroid feedback during fasting.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hypothyroidism leads to a change in the activity of iodo-
thyronine deiodinases, enzymes that are necessary for activa-
tion and inactivation of circulating thyroid hormones. The
regulation of these enzymes occurs in a tissue-speciﬁc manner
[1]. Deiodinase type II (DII), which converts T4 to the active
thyroid hormone, T3, is present in the central nervous system
[2,3], pituitary [4], brown adipose tissue [5], and placenta [6]
and it shows increased activity when plasma T4 declines. It
has been suggested that the major role of DII is to maintain
T3 homeostasis producing adequate intracellular levels of T3
in order to ensure all T3-dependent cellular functions in the tis-
sue [7,8].
Hypothyroidism due to failure of the thyroid gland induces
a rise in hypothalamic TRH levels [9], which, in turn, triggers
release of thyroid stimulating hormone (TSH) from the ante-
rior pituitary. This classic negative feedback of the thyroid axis
is paradoxically reversed during fasting whereby suppressed
circulating T4 levels coincide with suppressed production and
release of TRH in the hypothalamic paraventricular nucleus
and median eminence [10]. The central mechanism that under-*Corresponding author. Fax: +203 785 4747.
E-mail address: sabrina.diano@yale.edu (S. Diano).
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.07.035lies the emergence of this apparent paradox in thyroid feed-
back is not known.
We have previously shown [11,12] that an increase in the
enzymatic activity and mRNA levels of arcuate nucleus DII
occurs during short term fasting. T4 replacement in fasted ani-
mals did not reverse the increase in DII activity and mRNA
levels in the hypothalamus. Instead, DII activity during fasting
appears to be controlled by the inverse shift of circulating lep-
tin and corticosterone concentrations [12]. Thus, it is conceiv-
able that the increased DII activity during fasting underlies
elevated local T3 production (in spite of the systemic hypothy-
roidism), which, in turn, could trigger suppressed TRH pro-
duction and release. This study was undertaken to test this
hypothesis.2. Materials and methods
2.1. Experiment 1
Ten Sprague–Dawley male rats (200–250 g BW; Taconic Farms,
Inc.) were used. Each animal was implanted with one cannula into
the third ventricle (Bregma 0.8 mm) connected to a micro-osmotic
pump (Alzet Corp., Palo Alto, CA; 1.0 ll/h for 3 days). Animals were
divided into two experimental groups: a group (n = 5) infused with
0.9% saline and fed ad libitum, and a second group (n = 5) infused with
0.9% saline and fasted for 48 h. Animals were infused for the duration
of the experiment. Rats were sacriﬁced and the hypothalamus was col-
lected and immediately frozen and stored at 80 C until the activity
measurement was performed. The enzymatic activity was carried out
as previously described [12].
2.2. Experiment 2
Sixteen Sprague–Dawley male rats (200–250 g BW; Taconic Farms,
Inc.) were used. Each animal was implanted with one cannula into the
third ventricle (Bregma 0.8 mm) connected to a micro-osmotic pump
(Alzet Corp., Palo Alto, CA; 1.0 ll/h for 3 days). Animals were divided
into four experimental groups: a control group (n = 4) infused with
0.9% saline, a second group (n = 4) infused with 107 M iopanoic acid
(IOP; TCI America) diluted in 0.9% saline, a third group (n = 4) in-
fused with 105 M IOP diluted in 0.9% saline, and a fourth group
(n = 4) infused with 103 M IOP diluted in 0.9% saline. Animals were
infused for the duration of the experiment. Twenty-four hours after
implantation, all animals were food-deprived for 48 h. Animals were
then sacriﬁced and the hypothalamus, hippocampus, cerebellum, and
pituitary were collected and immediately frozen and stored at
80 C until the activity measurement was performed. The enzymatic
activity was carried out as previously described [12].
We deﬁne an undetectable level of DII enzymatic activity as a sam-
ple in which the amount of iodine released did not diﬀer from the blank
control (where the homogenate was omitted).blished by Elsevier B.V. All rights reserved.
Fig. 1. Graph showing hypothalamic DII activity in ICV saline-
treated rats that were either fed ad libitum (n = 5) or fasted for 48 h
(n = 5). Results are expressed as means ± S.E.M. *P < 0.001.
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Twenty Sprague–Dawley male rats (200–250 g BW; Taconic Farms,
Inc.) were used for this experiment implanted with a cannula into the
third ventricle (Bregma 0.8 mm) as described above. Animals were
divided into two experimental groups: a control group (n = 10) was in-
fused with 0.9% saline while the second group (n = 10) was infused
with 107 M IOP (TCI America) diluted in 0.9% saline (Alzet micro-
osmotic pump 1 ll/h, 3 days). All the animals were infused for the
duration of the experiment. Twenty-four hours after the implantation
of the pump, the animals were further divided in the following groups:
n = 5 infused with 0.9% saline and fed ad libitum; n = 5 infused with
0.9% saline and fasted for 48 h; n = 5 infused with 107 M IOP and
fed ad libitum; n = 5 infused with 107 M IOP and 48 h fasted. The
animals were then perfused and processed for semi-quantitative
in situ hybridization histochemistry.
An 826 bp fragment of complementary DNA (cDNA) of TRH was
ampliﬁed based on the RT-PCR reaction, using speciﬁc oligonucleo-
tide primers derived from the coding region of the rat TRH sequence
[13]. Total RNA was extracted from the hypothalamus by guanidium
thiocyanate–phenol–chloroform method using TriZol reagent (Life
Tecnologies, Grand Island, NY) and transcribed using the ﬁrst-strand
cDNA Synthesis Kit (Pharmacia Biotech, Piscataway, NJ). PCR reac-
tion was carried out using the following protocol: 3 lg cDNA tem-
plate, 0.5 lM primers, 1.25 mM MgCl2, 80 lM dNTP and 2 U Taq
DNA polymerase. The resulting fragment, puriﬁed from agarose gel
using QIA quick Gel Extraction Kit (QIAGEN Inc.), was digested
with EcoRI and BamHI, inserted in pBluescript vector (Stratagene,
La Jolla, CA). Linearized DNA was transcribed using SP6 polymerase
(antisense cRNA probe) and T7 polymerase (sense cRNA probe;
Riboprobe Combination System SP6/T7, Promega Corporation, Mad-
ison, WI) and labeled with 35S-UTP (Amersham; 10 mCi/ml). The
hybridization was carried out as previously described [11].
The density of the hybridization product was assessed in the diﬀerent
experimental groups. In order to digitally analyze, quantitate and com-
pare the amount of TRH mRNA, an Image-1/AT image processor
(Universal Imaging Corporation, West Chester, PA) using an Olympus
IMT-2 inverted microscope with dark ﬁeld optics (Olympus Corpora-
tion, Lake Success, New York) and a Hamamatsu CCD camera (Ham-
amatsu Photonics, Hamamatsu, Japan) was employed. Six sections per
animal were selected from the same area to assess the intensity of the
hybridization product. The total surface covered by the hybridization
product was assessed within a test region measuring 2 · 105 mm2 that
contains the paraventricular nucleus. The threshold for measurement
was assessed for each slide by determining the background labeling
in the nearby ventromedial nucleus.
2.4. Experiment 4
Twenty male Sprague–Dawley rats (200–250 g BW; Taconic Farm,
Inc.) were used in this study. Each animal was implanted with one
cannula into the third ventricle (Bregma 0.8 mm) connected to a mi-
cro-osmotic pump (Alzet Corp., Palo Alto, CA; 1.0 ll/h for 3 days).
Animals were divided into four experimental groups: group 1 (n = 4)
and group 2 (n = 4) infused with 0.9% saline, group 3 (n = 4) and group
4 infused with 107 M IOP (TCI America) diluted in 0.9% saline. Rats
were infused for the duration of the experiment. Twenty-four hours
after implantation, groups 2 and 4 were food-deprived for 48 h. All
animals were then sacriﬁced and the hypothalamus was collected and
immediately frozen and stored at 80 C.
Triiodothyronine (T3) was extracted from the hypothalamus by add-
ing methanol 95% containing PTU 104 M. Tissues were homogenized
and centrifuged at 13000 rpm and the pellets re-suspended twice using
methanol solution. The supernatants were evaporated to dryness and
resuspended in GAB buﬀer (0.2 M glycine/0.13 M acetate with 0.02%
BSA). T3 was determined by radioimmunoassay system (RIA). Sam-
ples and standard curve were incubated at 4 C with polyclonal anti-
body against T3 (Fitzgerald Industries International, Concord, MA)
in RIA buﬀer GAB. Three days later, 10000 cpm of radiolabeled
[125I] T3 (Speciﬁc activity 2200 Ci/mmol; Perkin–Elmer Life Sciences,
Boston MA) was added to each tube. After two days of incubation,
a rabbit gamma globulin (Jackson ImmunoResearch Laboratories) di-
luted in 0.1 M EDTA and 16% polyethylene glycol with goat antirab-
bit IgG (Antibodies Incorporated, Davis CA) in GA buﬀer (0.2 M
glycine/0.13 M acetate) was added to precipitate the antibody–T3 com-
plex. After centrifugation the precipitates were counted in a c-counter.
T3 is expressed in picogram per milligram of weight tissue.2.5. Statistical analyses
Means were compared between experimental groups using one-way
analysis of variance (ANOVA) with mean comparisons by the Stu-
dent–Newman–Keuls method. A level of conﬁdence of P < 0.05 was
used to determine signiﬁcant diﬀerences.3. Results
3.1. Experiment 1
As previously reported by our group [11,12], fasting in saline
infused animals (96.33 ± 1.69 fmol/h/mg protein) increased
DII enzymatic activity compared to ad libitum fed rats
(79.75 ± 1.55 fmol/h/mg protein; Fig. 1).
3.2. Experiment 2
The intracerebroventricular infusion of IOP in fasted rats
showed that IOP at a concentration of 107 M can selectively
inhibit the activity of DII in the hypothalamus without inter-
fering with its activity in other brain regions or in the pituitary
(Table 1). In the hypothalamus, IOP infusion inhibits DII
activity at all three concentrations used (undetectable levels),
while in the pituitary, as well as in the cerebellum, a partial
inhibition (about 45% and 58%, respectively) occurs at a con-
centration of 105 M, and a total inhibition occurs at 10 3 M
(Table 1). In the hippocampus, only the 103 M concentration
induces a complete inhibition of DII activity, while all of the
other concentrations had no eﬀect on the enzyme function
(Table 1).
3.3. Experiment 3
As previously shown in fasted compared to fed rats, in situ
hybridization for TRH mRNA in the paraventricular nucleus
of the hypothalamus of saline infused rats showed that fasting
induces a decrease in TRH mRNA levels (OD = 1801 ± 177)
compared to fed control animals (OD = 2850 ± 50; P < 0.05;
Fig. 2). When the animals were treated with IOP, fasting
blunted the decrease in TRH mRNA levels (OD =
2293 ± 178) compared to that of IOP-treated fed animals
(OD = 2577 ± 123; P > 0.05; Fig. 2). In fed groups, IOP treat-
ment slightly but not signiﬁcantly decreased TRH mRNA lev-
els compared to the saline-treated rats (P > 0.05). On the other
hand, in IOP-treated fasted rats the levels of TRH mRNA was
statistically higher than the levels of the saline-treated fasted
group (P < 0.05).
Table 1
DII activity measurements (expressed in fmoles I/h/mg protein) in the pituitary, hypothalamus, hippocampus and cerebellum of third ventricle
implanted rats (n = 4 for each group) with saline, 107, 105 and 103 M iopanoic acid (IOP)
Saline 107 M IOP 105 M IOP 103 M IOP
Pituitary 1014 ± 39.37 1077.5 ± 13.44 453.67 ± 30.36a,b NDa,b,c
Hypothalamus 96.33 ± 1.69 NDa NDa NDa
Hippocampus 68.0 ± 3.0 72.67 ± 1.15 80.33 ± 6.75 NDa,b,c
Cerebellum 53.67 ± 5.25 50.33 ± 3.18 31.0 ± 5.77a,b NDa,b,c
Results are expressed as means ± S.E.M.
ND, not detectable.
aP < 0.05 compared to the saline control.
bP < 0.05 compared to the 107 M IOP.
cP < 0.05 compared to the 105 M IOP.
Fig. 2. In situ hybridization for TRH mRNA in the PVN revealed that while fasting suppressed TRH mRNA levels in the saline-treated animals
(P < 0.05), ICV IOP (dissolved in saline) injections blunted the fasting-induced decline in TRH mRNA levels of the PVN. Results are expressed as
means ± S.E.M. *P < 0.05 compared to saline-treated fed, IOP-treated fed and fasted rats. P > 0.05 between fed saline and fed IOP-treated rats. OD,
arbitrary optical density.
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In the present as well as previous studies, we showed [11,12]
that during food deprivation DII activity levels are increased
in the hypothalamus. To assess whether this elevation in activ-
ity also induces increased tissue levels of T3, we performed T3
measurements in the hypothalamic tissue of fasted and fed ani-
mals. Moreover, to determine whether the eﬀect of IOP in
blunting TRH mRNA decline during fasting is due to a change
in the tissue T3, we assessed hypothalamic T3 levels in IOP in-
fused rats that were either fasted or fed ad libitum. Hypotha-
lamic T3 levels were signiﬁcantly higher in saline-treated
fasted rats (2.32 ± 0.13 pg/mg wet tissue) compared to the sal-
ine-treated ad libitum fed animals (1.71 ± 0.03 pg/mg wet tis-
sue; Fig. 3). On the other hand, in IOP-infused rats, foodFig. 3. Graph showing hypothalamic T3 levels in fed and fasted rats
after ICV injection of saline or IOP (n = 4 for each group). Results are
expressed as means ± S.E.M. *P < 0.05 compared to saline-treated fed,
IOP-treated fed and fasted rats. P > 0.05 between fed saline, fed IOP
and fasted IOP-treated rats.deprivation did not aﬀect hypothalamic T3 levels
(1.81 ± 0.03 pg/mg wet tissue) and was not signiﬁcantly diﬀer-
ent from the levels of the fed animals (1.95 ± 0.04 pg/mg wet
tissue). No signiﬁcant diﬀerences (P > 0.05) in T3 levels were
found between the fed saline-treated, fed IOP-treated and
fasted IOP-treated rats.4. Discussion
The results of this study suggest that activation of hypotha-
lamic DII during fasting contributes to elevated local T3 pro-
duction, which, in turn, could trigger suppression of TRH
mRNA levels in the paraventricular nucleus. Although IOP
treatment did not reduce hypothalamic T3 levels in fed ani-
mals, it did prevent T3 elevation induced by fasting. We found
that in fed animals treated with IOP hypothalamic T3 levels
were slightly elevated compared to the saline-treated fed ani-
mals and this could be the reason for the slight suppression
of TRH levels in the IOP-treated fed group. While it may ap-
pear to be a paradox, we suggest that the elevated hypotha-
lamic T3 levels in IOP-treated fed group could be due to
increased transport of circulating T3 to the hypothalamus
(rather than local formation). However, fasting-induced DII
increase was blocked by IOP hence the diminished suppression
of TRH.
To block DII activity, we employed IOP. IOP has been pre-
viously shown to be a potent competitive inhibitor of DII
in vivo as well as in vitro [14–17].
In our study, we observed that IOP had a diﬀerential eﬀect
in all brain areas examined. We propose that this diﬀerential
eﬀect is the consequence of the accessibility of IOP. Because
the cannulae in the third ventricle were positioned in the
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reasonable to hypothesize that the strongest eﬀect of IOP at
the lower dose (107 M) was found in the hypothalamus,
compared to the hippocampus, cerebellum and pituitary
gland.
In the central nervous system, the majority of the active
form of thyroid hormone, T3, derives from the intracellular
5 0-monodeiodination of T4 by type II 5 0-monodeiodinase
(DII) [18,19]. DII activity measurements in rat brain have
shown the highest enzymatic activity in the arcuate nu-
cleus/median eminence (ARC/ME) fragments of the hypo-
thalamus, while a minimal activity has been found in the
paraventricular nucleus (PVN), where TRH-containing cells
are located [2]. The appearance of DII mRNA in the epen-
dymal zone and the ME [3], together with our previous
observation of glial ﬁbrillary acidic protein (GFAP) in cells
expressing DII mRNA [20], an earlier report [21] on the
expression of DII in glial cells in neonatal rat brain and
our recent ﬁnding of DII immunoreactivity in the hypothal-
amus [22] strongly indicate that DII producing cells are
astrocytes and tanycytes. These glial cells provide an exten-
sive network of cellular processes in the ARC [23,24] and
suggest a paracrine action on PVN-projective ARC neurons
via the production of thyroid hormones.
We have recently shown [12] that during food deprivation,
the increased DII activity is due to an inverse shift in circu-
lating levels of corticosterone and leptin. Now we showed
that increased DII activity during fasting triggers elevated
local T3 levels and suppression of DII activity by IOP pre-
vents this elevation. Furthermore, IOP infusion prevents
fasting-triggered decrease in TRH mRNA levels. Thus, we
propose that this previously unsuspected existence of hypo-
thalamic hyperthyroidism in the face of systemic hypothy-
roidism during fasting may be responsible for the decline
of TRH mRNA levels and for the reversal of negative feed-
back of the thyroid axis.
The arcuate nucleus has been found to contain an abun-
dant population of thyroid receptor-producing neuronal
nuclei [25], as well as populations producing various regula-
tory peptides and neurotransmitters such as neuropeptide
Y, opioid peptides, growth hormone releasing hormone and
dopamine, all of which are known to inﬂuence the production
and release of TRH [26–28]. We have demonstrated the exis-
tence of a monosynaptic pathway between the arcuate nu-
cleus that contains DII-producing glial cells, and the
paraventricular TRH neurons that project to the median emi-
nence with direct access to fenestrated capillaries [20]. In
addition, we [29] and others [30] have shown that the arcuate
nucleus NPY/AgRP neurons provide a massive inhibitory in-
put on TRH cell bodies and proximal dendrites via symmet-
ric synapses. Another study [31] also reported that TRH cells
are symmetrically contacted by nerve terminals containing
AgRP, which is co-produced in the NPY arcuate neurons.
In the present study we showed that activation of DII induces
alterations in arcuate nucleus T3 levels and that may be
responsible for the decrease in TRH mRNA levels during
fasting. Thus we hypothesize that the increased in T3 levels
during food deprivation could aﬀect and altered neuropeptide
expression in leptin-responsive arcuate neurons that strongly
project to paraventricular TRH neurons. Studies are under-
way to delineate this signaling modality in the hypothalamic
regulation of the thyroid axis.Acknowledgments: This work was supported by NIH Grant DK
061619 (to S.D.). We thank Jayodita Sanghvi for her technical
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